Cas:1040079-19-3 2,3-Dichloro-N-(2-fluorobenzyl)aniline, 97% manufacturer & supplier

Chemical Name:2,3-Dichloro-N-(2-fluorobenzyl)aniline, 97%

CAS.NO:1040079-19-3

Synonyms:2,3-Dichloro-N-(2-fluorobenzyl)aniline, 97%

Molecular Formula:C₁₃H₁₀Cl₂FN

Molecular Weight:270.1296032

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2,3-Dichloro-N-(2-fluorobenzyl)aniline, 97% chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,3-Dichloro-N-(2-fluorobenzyl)aniline, 97% physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,3-Dichloro-N-(2-fluorobenzyl)aniline, 97% Use and application,2,3-Dichloro-N-(2-fluorobenzyl)aniline, 97% technical grade,usp/ep/jp grade.

Related News: This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care. 2,3-Dichloro-N-(2-fluorobenzyl)aniline, 97% manufacturer Citizens and residents will be allowed entry to New Zealand, but will be required to quarantine themselves for 14 days, Prime Minister Jacinda Ardern said. 2,3-Dichloro-N-(2-fluorobenzyl)aniline, 97% supplier Citizens and residents will be allowed entry to New Zealand, but will be required to quarantine themselves for 14 days, Prime Minister Jacinda Ardern said. 2,3-Dichloro-N-(2-fluorobenzyl)aniline, 97% vendor The researchers also found that Black women are much less likely to undergo genetic counseling and testing, largely due to differences in physician recommendations or access to care. 2,3-Dichloro-N-(2-fluorobenzyl)aniline, 97% factory Taking Minuo Huawei as an example, in 2016, the capacity utilization rate and production-sales ratio of its multiple drug substance varieties reached more than 90%. Therefore, domestic API companies have expanded their production capacity in recent years to meet the growing demand for APIs.